This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 54/1/32    most recent HYPERTENSIONAHA.109.131300v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Calhoun, D. A. Articles by Glazer, R. D. PubMed PubMed Citation Articles by Calhoun, D. A. Articles by Glazer, R. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AMLODIPINE BESYLATE HYDROCHLOROTHIAZIDE Medline Plus Health Information High Blood Pressure Related Collections Clinical Studies Related Article

(Hypertension. 2009;54:32.)
© 2009 American Heart Association, Inc.

Original Articles

Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide

A Randomized Clinical Trial

David A. Calhoun; Yves Lacourcière; Yann Tong Chiang; Robert D. Glazer

From the Vascular Biology and Hypertension Program, Sleep/Wake Disorders Center, University of Alabama at Birmingham (D.A.C.); Centre Hôpitalier de l'Université Laval (Y.L.), Ste-Foy, Québec, Canada; and Novartis Pharmaceuticals Corporation (Y.T.C., R.D.G.), East Hanover, NJ.

Correspondence to David A. Calhoun, Vascular Biology and Hypertension Program, Sleep/Wake Disorders Center, University of Alabama at Birmingham, Birmingham, AL 35294. E-mail dcalhoun{at}uab.edu

Many patients with hypertension require 3 agents to achieve target blood pressure (BP). The efficacy/safety of the dual combinations of valsartan (Val)/hydrochlorothiazide (HCTZ) and amlodipine (Aml)/Val in hypertension are well established. This randomized, double-blind study evaluated the efficacy/safety of triple therapy with Aml/Val/HCTZ for moderate or severe hypertension (mean sitting systolic BP: 145 mm Hg; mean sitting diastolic BP: 100 mm Hg). The study included a single-blind, placebo run-in period, followed by double-blind treatment for 8 weeks; patients were randomly assigned to 1 of 4 groups titrated to Aml/Val/HCTZ 10/320/25 mg, Val/HCTZ 320/25 mg, Aml/Val 10/320 mg, or Aml/HCTZ 10/25 mg once daily. Dual-therapy recipients received half of the target doses of both agents for the first 2 weeks, titrating to target doses during week 3. Those on triple therapy received Val/HCTZ 160.0/12.5 mg during week 1, Aml/Val/HCTZ 5.0/160.0/12.5 mg during week 2, and target doses of all 3 of the agents during week 3. Of the 4285 patients enrolled, 2271 were randomly assigned to treatment, and 2060 completed the study. Triple therapy was significantly superior to all of the dual therapies in reducing mean sitting systolic BP and mean sitting diastolic BP from baseline to end point (all P<0.0001). Significantly more patients on triple therapy achieved overall BP control (<140/90 mm Hg; P<0.0001) and systolic and diastolic control (P0.0002) compared with each dual therapy. Aml/Val/HCTZ was well tolerated. The benefits of triple therapy over dual therapy were observed regardless of age, sex, race, ethnicity, or baseline mean sitting systolic BP. In conclusion, this study demonstrates the efficacy/safety of treating moderate and severe hypertension with Aml/Val/HCTZ 10/320/25 mg.

Key Words: amlodipine • valsartan • hydrochlorothiazide • hypertension • triple therapy

Related Article:

Triple Fixed-Dose Combination Therapy: Back to the Past

Henry R. Black
Hypertension 2009 54: 19-22. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				H. R. Black Triple Fixed-Dose Combination Therapy: Back to the Past Hypertension, July 1, 2009; 54(1): 19 - 22. [Full Text] [PDF]